NCT06193122View on ClinicalTrials.gov

Three-Dimensional Ultrasound and Spectroscopy as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment

Not yet recruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2029

Conditions

Breast Cancer

Interventions

DEVICE

Ultrasound imaging 3D and Spectroscopy

Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors

lead

Sunnybrook Health Sciences Centre

OTHER

NCT06193122 - Three-Dimensional Ultrasound and Spectroscopy as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment | Biotech Hunter | Biotech Hunter